Şehnaz Olgun Yıldızeli1, Atakan Erkılınç2, Mehmed Yanartaş3, Serpil Taş3, Hasan Sunar3, Emre Gürcü2, Bedrettin Yıldızeli4. 1. Department of Chest Diseases and Intensive Care, Medicine Faculty of Marmara University, İstanbul, Turkey. 2. Department of Anesthesiology and Reanimation, University of Health Sciences, Kartal Koşuyolu Training and Research Hospital, İstanbul, Turkey. 3. Department of Cardiovascular Surgery, University of Health Sciences, Kartal Koşuyolu Training and Research Hospital, İstanbul, Turkey. 4. Department of Thoracic Surgery, Medicine Faculty of Marmara University, İstanbul, Turkey.
Abstract
BACKGROUND: This study aims to evaluate our approaches and outcomes in patients who developed hemoptysis following pulmonary endarterectomy. METHODS: Pulmonary endarterectomy was performed in 460 patients at Kartal Koşuyolu Training and Research Hospital between March 2011 and September 2017. Clinical characteristics, perioperative management and postoperative outcomes of 10 patients (2.1%) (4 males, 6 females; mean age 48.3±16.5 years; range 21 to 76 years) with massive pulmonary hemorrhage following pulmonary endarterectomy were evaluated. RESULTS: Mean period of diagnosis for chronic thromboembolic pulmonary hypertension was 17±13.6 months. All patients were New York Heart Association functional class II (n=2), III (n=5) or IV (n=3). For the treatment of massive pulmonary hemorrhage, intraoperative extracorporeal membrane oxygenation was used in six patients (60%), while conservative treatments were used in four patients (40%). In-hospital mortality rate was 50% (n=5); the causes for mortality were septic shock in two patients, multiple organ failure in two patients and intracranial hemorrhage in one patient. Survival was achieved in two patients on extracorporeal membrane oxygenation and three patients receiving conservative treatment. Functional and hemodynamic improvement was observed in all surviving patients. CONCLUSION: Despite the relatively low incidence of massive pulmonary hemorrhage after pulmonary endarterectomy, it is a potentially fatal complication. Our approach focuses on early diagnosis with a multidisciplinary team and management with bronchoscopy, bronchial blockers and use of extracorporeal membrane oxygenation. The choice of treatment depends on the site and origin of the hemorrhage, the availability of equipment and expertise, and the potential short- and long-term advantages and disadvantages.
BACKGROUND: This study aims to evaluate our approaches and outcomes in patients who developed hemoptysis following pulmonary endarterectomy. METHODS: Pulmonary endarterectomy was performed in 460 patients at Kartal Koşuyolu Training and Research Hospital between March 2011 and September 2017. Clinical characteristics, perioperative management and postoperative outcomes of 10 patients (2.1%) (4 males, 6 females; mean age 48.3±16.5 years; range 21 to 76 years) with massive pulmonary hemorrhage following pulmonary endarterectomy were evaluated. RESULTS: Mean period of diagnosis for chronic thromboembolic pulmonary hypertension was 17±13.6 months. All patients were New York Heart Association functional class II (n=2), III (n=5) or IV (n=3). For the treatment of massive pulmonary hemorrhage, intraoperative extracorporeal membrane oxygenation was used in six patients (60%), while conservative treatments were used in four patients (40%). In-hospital mortality rate was 50% (n=5); the causes for mortality were septic shock in two patients, multiple organ failure in two patients and intracranial hemorrhage in one patient. Survival was achieved in two patients on extracorporeal membrane oxygenation and three patients receiving conservative treatment. Functional and hemodynamic improvement was observed in all surviving patients. CONCLUSION: Despite the relatively low incidence of massive pulmonary hemorrhage after pulmonary endarterectomy, it is a potentially fatal complication. Our approach focuses on early diagnosis with a multidisciplinary team and management with bronchoscopy, bronchial blockers and use of extracorporeal membrane oxygenation. The choice of treatment depends on the site and origin of the hemorrhage, the availability of equipment and expertise, and the potential short- and long-term advantages and disadvantages.
Authors: Patricia A Thistlethwaite; Michael M Madani; Aaron D Kemp; Mary Hartley; William R Auger; Stuart W Jamieson Journal: Ann Thorac Surg Date: 2006-12 Impact factor: 4.330
Authors: Marius Berman; Steven Tsui; Alain Vuylsteke; Andrew Snell; Simon Colah; Ray Latimer; Roger Hall; Joseph E Arrowsmith; John Kneeshaw; Andrew A Klein; David P Jenkins Journal: Ann Thorac Surg Date: 2008-10 Impact factor: 4.330
Authors: Marco Morsolini; Andrea Azzaretti; Giulio Orlandoni; Andrea M D'Armini Journal: J Thorac Cardiovasc Surg Date: 2013-01-09 Impact factor: 5.209
Authors: Joanna Pepke-Zaba; Marion Delcroix; Irene Lang; Eckhard Mayer; Pavel Jansa; David Ambroz; Carmen Treacy; Andrea M D'Armini; Marco Morsolini; Repke Snijder; Paul Bresser; Adam Torbicki; Bent Kristensen; Jerzy Lewczuk; Iveta Simkova; Joan A Barberà; Marc de Perrot; Marius M Hoeper; Sean Gaine; Rudolf Speich; Miguel A Gomez-Sanchez; Gabor Kovacs; Abdul Monem Hamid; Xavier Jaïs; Gérald Simonneau Journal: Circulation Date: 2011-10-03 Impact factor: 29.690
Authors: Eckhard Mayer; David Jenkins; Jaroslav Lindner; Andrea D'Armini; Jaap Kloek; Bart Meyns; Lars Bo Ilkjaer; Walter Klepetko; Marion Delcroix; Irene Lang; Joanna Pepke-Zaba; Gerald Simonneau; Philippe Dartevelle Journal: J Thorac Cardiovasc Surg Date: 2011-03 Impact factor: 5.209
Authors: Stuart W Jamieson; David P Kapelanski; Naohide Sakakibara; Gerard R Manecke; Patricia A Thistlethwaite; Kim M Kerr; Richard N Channick; Peter F Fedullo; William R Auger Journal: Ann Thorac Surg Date: 2003-11 Impact factor: 4.330